Price range: 109,90 € through 179,90 €
Royal Peptides Dosing Pen – GLP-3 R3T 20 mg/3 ml
A modern and practical dosing pen designed for precise and convenient administration of research compounds. Its elegant design, compact construction, and user-friendly operation enable efficient handling in laboratory environments.
GLP-3 R3T is an innovative experimental peptide compound belonging to the class of so-called Triple Agonists. It is currently the subject of intensive scientific research due to its potential effects on metabolism, body weight regulation, and energy balance through the simultaneous activation of multiple key hormonal receptors.
The pen is supplied in a practical travel case together with a cooling gel pack, both of which are included in the product price.
Needles are not included in the package and are not available through our company.
This product is intended exclusively for scientific and research purposes.
GLP-3 R3T – 20 mg/3 ml Dosing Pen (Triple Agonist)
GLP-3 R3T represents the latest generation of experimental peptide compounds currently being investigated in advanced scientific research focused on body weight regulation, metabolism, and overall energy balance. This compound uniquely functions as a triple receptor agonist, simultaneously targeting the GLP-1, GIP, and glucagon receptors. Through this triple mechanism of action, it influences multiple metabolic pathways at the same time, including satiety signaling, efficient glucose metabolism, and the activation of fat stores as a source of energy.
The dosing pen contains 20 mg of highly purified active compound in 3 ml of solution, corresponding to a concentration of approximately 6.67 mg/ml. For precise dosing within research protocols:
1 ml = 100 units (IU) = 100 clicks
0.5 ml (one full rotation of the mechanism) = 50 clicks
Example research doses:
This mechanical dosing system ensures exceptional precision, repeatability, and flexibility when setting microdoses according to the requirements of individual laboratory protocols.
This compound represents one of the most advanced developments in modern metabolic research. The synergistic activation of three different hormonal receptors enables a significantly more comprehensive influence on energy expenditure and metabolic efficiency than earlier single-target compounds.
Activation of the GLP-1 and GIP receptors has been associated in research studies with modulation of food intake and optimization of glycemic control. Additional activation of the glucagon receptor promotes thermogenesis and increases basal energy expenditure. Current research suggests that this comprehensive approach produces more pronounced metabolic effects, making the compound an important subject of investigation in relation to obesity, metabolic syndrome, and insulin resistance.
This innovative triple agonist (originally developed in biomedical laboratories under the LY-343 series designation) has demonstrated highly promising results in Phase II clinical studies. Scientific publications in leading medical journals, including The New England Journal of Medicine, have reported unprecedented effects on body fat reduction and overall improvement of metabolic parameters among study participants.
Additional data from preclinical and ongoing clinical research are available through internationally recognized scientific databases such as PubMed and ClinicalTrials.gov. Current research focuses on long-term glycemic stability, lipid profile optimization, and improvements in cellular energy utilization.
The Royal Peptides dosing pen provides a modern, safe, and highly sterile solution for handling this advanced research compound under controlled laboratory conditions.
This product is intended exclusively for scientific and research purposes. Not for human consumption.
